Clinical Trial Details

A Phase 2 Study of Pembrolizumab in Patients With Histiocyte/Dendritic Cell Neoplasms and Biologically Selected Subtypes of Relapsed/Refractory Aggressive Lymphomas

Categories (click each to see list of all clinical trials associated with that category): Lymphoma/Chronic lymphocytic leukemia (CLL)

Current Status: Open to accrual

Phase: II

Principal Investigator: Lunning, Matthew

Contact Information:
Sarah Snook
sarah.snook@unmc.edu

Eligibility: https://clinicaltrials.gov/ct2/show/NCT03316573#eligibility

Summary
Primary Objectives To examine the efficacy (overall response rate) of pembrolizumab in patients with biologically selected subsets of relapsed/refractory (R/R) biologically selected subgroups of lymphoma, using 2014 Lugano criteria (31, appendix C). Secondary Objectives To examine the rates of complete response, partial response, stable disease, and progressive disease with pembrolizumab in the group of patients with biologically selected subsets of R/R biologically selected subgroups of lymphoma and histiocyte/dendritic cell neoplasms, using the 2014 Lugano criteria (31, appendix C) To examine the efficacy (overall response rate) of pembrolizumab in patients with histiocytic sarcoma, follicular dendritic cell sarcoma, and interdigitating dendritic cell sarcoma using 2014 Lugano criteria (31, appendix C). To examine the duration of response, duration of complete response, and progressionfree survival associated with pembrolizumab treatment in this patient population, using the 2014 Lugano criteria (31, appendix C). To examine the rates of overall, complete and partial response as well as stable disease, progression-free survival and duration of remission using the LyRIC criteria [32, appendix B] To examine the safety and toxicity of pembrolizumab in patients with biologically selected subsets of R/R lymphoma and histiocyte/dendritic cell neoplasms. Exploratory Objectives To evaluate the expression of PD-L1, genetic integrity of PD-L1/2 locus, and latent viral infection in a selected subset tumors, and preliminarily correlate those with clinical outcome. To study the immune microenvironment and circulating lymphocyte subsets in patients before and after